September 16, 2025
ISOFOL PRESENTED AT AKTIEDAGARNA
IN SWEDEN ON SEPTEMBER 16
About Isofol
Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with a new dosing regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- May 19, 2026 - May 19, 2026
Interim Report January-March 2026 - May 19, 2026 - May 19, 2026
Annual General Meeting 2026, Gothenburg
Media – Lates pressreleases
Isofol’s clinical study with arfolitixorin reaches another important milestone
GOTHENBURG, Sweden, September 30, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed the second dose…
Isofol completes transfer of shares to Solasia Pharma following a successful rights issue
GOTHENBURG, Sweden, September 26, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the transfer of the shares subscribed by the…
Isofol Medical AB (publ) publishes interim report, January–June 2025
GOTHENBURG, Sweden, August 26, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2025 is…
INVESTORS – latest reports and presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.
